

IN THE CLAIMS:

Please amend the claims as follows:

1. (Amended) A humanized antibody that binds ICAM-1, said antibody selected from: ~~SEQ ID NO:1 and 3 (HumA); SEQ ID NO:5 and 7 (HumB) ; SEQ ID NO:9 and 11 (HumC); SEQ ID NO:13 and 15 (HumD); SEQ ID NO:17 and 19 (HumE); SEQ ID NO:21 and 23 (HumF); SEQ ID NO:25 and 27 (HumG); SEQ ID NO:29 and 31 (HumH); and SEQ ID NO:33 and 35 (HumI).~~
2. (Amended) A subsequence of the antibody of claim 1, said antibody subsequence capable of binding an ICAM-1 epitope, and wherein the variable framework region of said subsequence has one or more amino acids of a human consensus variable framework region sequence.
3. (Amended) The ~~humanized~~ antibody subsequence of claim 2, wherein the antibody subsequence comprises a single chain, Fab, Fab' or (Fab)₂ fragment.
4. (Amended) The humanized antibody of claim 1, said antibody having one or more amino acid substitutions, provided that said substitution when in the variable framework region is an amino acid based upon a human consensus variable framework region sequence, and said substituted antibody is capable of binding an ICAM-1 epitope.
5. (Amended) A humanized antibody that binds ICAM-1 and inhibits pathogen infection of cells expressing ICAM-1, wherein the variable framework region has one or more amino acids of a human consensus variable framework region sequence, and wherein the protective efficacy is at least equivalent to mouse monoclonal antibody denoted as 1A6.
6. (Previously Presented) The humanized antibody of claim 5, said antibody having a protective efficacy at least 2 times greater than the non-humanized antibody.
7. (Previously Presented) The humanized antibody of claim 5, said antibody having a protective efficacy at least 5 times greater than the non-humanized antibody.
8. (Previously Presented) The humanized antibody of claim 5, said antibody having a protective efficacy at least 10 times greater than the non-humanized antibody.
9. (Previously Presented) The humanized antibody of claim 5, said antibody having a protective efficacy at least 20 times greater than the non-humanized antibody.
10. (Previously Presented) The humanized antibody of claim 5, said antibody having a protective efficacy at least 30 times greater than the non-humanized antibody.

11. (Previously Presented) The humanized antibody of claim 5, wherein the pathogen is human rhinovirus (HRV).
12. (Amended) The humanized antibody of claim 5, wherein the pathogen is ~~coxsackie~~ coxsackie A virus, or respiratory syncytial virus, ~~or malaria~~.
13. (Previously Presented) The humanized antibody of claim 5, wherein the antibody is an intact immunoglobulin molecule comprising 2 full-length heavy chains and 2 full-length light chains.
14. (Previously Presented) The humanized antibody of claim 5, wherein the antibody is an antibody subsequence that binds to ICAM-1.
15. (Previously Presented) The humanized antibody of claim 14, wherein the antibody subsequence comprises a single chain, Fab, Fab' or (Fab)₂ fragment.
16. (Amended) The humanized antibody of claim 1 or 5, wherein the antibody is multispecific or multifunctional.[:;]
17. (Amended) The humanized antibody of claim 1 or 5, wherein the antibody is linked to one or more identical or different antibodies to form a multimer.
18. (Previously Presented) The humanized antibody of claim 17, wherein the multimer comprises a homo- or hetero-dimer, trimer, or tetramer.
19. (Previously Presented) The humanized antibody of claim 17, wherein the multimer is formed via a multimerization domain.
20. (Previously Presented) The humanized antibody of claim 19, wherein the multimerization domain comprises a human amino acid sequence.
21. (Previously Presented) The humanized antibody of claim 19, further comprising a linker located between the multimerization domain and the antibody.
22. (Amended) A humanized antibody that inhibits human rhinovirus (HRV) infection of cells comprising the amino acid sequence set forth in any of ~~SEQ ID NO:1 and 3 (HumA); SEQ ID NO:5 and 7 (HumB); SEQ ID NO:9 and 11 (HumC); SEQ ID NO:13 and 15 (HumD); SEQ ID NO:17 and 19 (HumE); SEQ ID NO:21 and 23 (HumF); SEQ ID NO:25 and 27 (HumG); SEQ ID NO:29 and 31 (HumH); and SEQ ID NO:33 and 35 (HumI);~~ or a subsequence thereof, wherein the variable framework region of said subsequence has one or more amino acids of a human consensus variable framework region sequence.

23. (Previously Presented) The humanized antibody of claim 22, wherein the antibody is an immunoglobulin molecule comprising 2 full-length heavy chain polypeptides and 2 full-length light chain polypeptides.
24. (Previously Presented) The humanized antibody of claim 22, wherein the subsequence comprises a single chain, Fab, Fab' or (Fab)₂ fragment.
25. (Previously Presented) The humanized antibody of claim 22, wherein the antibody is linked with other identical or different antibodies to form a multimer.
26. (Previously Presented) The humanized antibody of claim 25, wherein the multimer comprises a homo- or hetero-dimer, trimer, or tetramer.
27. (Previously Presented) The humanized antibody of claim 25, wherein the different antibodies are human, humanized or non-human.
28. (Amended) A nucleic acid sequence encoding a humanized antibody of claim 1 or 22 or a subsequence thereof, wherein the variable framework region of said subsequence has one or more amino acids of a human consensus variable framework region sequence.
29. (Previously Presented) An expression cassette comprising the nucleic acid sequence of claim 28 operably linked to an expression control element.
30. (Previously Presented) A vector comprising the nucleic acid sequence of claim 29.
31. (Previously Presented) The vector of claim 29, wherein the nucleic acid sequence is operably linked to an expression control element.
32. (Previously Presented) A cell comprising the nucleic acid sequence of claim 28.
33. (Previously Presented) The cell of claim 31, wherein the cell is prokaryotic or eukaryotic.
34. (Previously Presented) A pharmaceutical composition comprising a humanized antibody of claim 1 or 5, and a pharmaceutically acceptable carrier.
35. (Previously Presented) The pharmaceutical composition of claim 34, wherein the carrier is compatible with inhalation or nasal delivery to a subject.
36. (Previously Presented) A method of inhibiting pathogen infection of a cell comprising contacting a pathogen or a cell with an amount of a humanized antibody of claims 1 or 5, sufficient to inhibit pathogen infection of the cell.
37. (Previously Presented) The method of claim 36, wherein the cell is present in a subject.
38. (Previously Presented) The method of claim 37, wherein the cell is an epithelial cell.
39. (Previously Presented) The method of claim 37, wherein the cell expresses ICAM-1.

40. (Amended) A method of inhibiting HRV infection of a cell comprising contacting HRV or a cell susceptible to HRV infection with an amount of a humanized antibody of claim [21] 22 effective to inhibit HRV infection of the cell.
41. (Previously Presented) The method of claim 40, wherein the cell is present in a subject.
42. (Previously Presented) The method of claim 41, wherein the subject has or is at risk of having asthma.
43. (Previously Presented) The method of claim 40, wherein the antibody binds to an antigen present on the surface of the cell.
44. (Previously Presented) The method of claim 40, wherein the cell expresses ICAM-1.
45. (Previously Presented) The method of claim 40, wherein the cell is an epithelial cell.
46. (Previously Presented) The method of claim 40, wherein the humanized antibody is administered locally.
47. (Amended) The method of claim 40, wherein the humanized antibody is administered via inhalation or ~~intranassaly~~ intranassaly.
48. (Amended) A method of inhibiting HRV infection, inhibiting HRV progression or treating HRV infection of a subject comprising administering to a subject having or at risk of having HRV infection an amount of a humanized antibody of claim ~~21~~ 22 effective to inhibit, inhibit progression or treat HRV infection of the subject.
49. (Previously Presented) The method of claim 48, wherein the humanized antibody is administered locally.
50. (Amended) The method of claim 48, wherein the humanized antibody is administered via inhalation or ~~intranassaly~~ intranassaly.
51. (Previously Presented) The method of claim 48, wherein the subject has or is at risk of having asthma.
52. (Previously Presented) The method of claim 48, wherein the subject is a newborn or between the ages of 1 to 5, 5 to 10 or 10 to 18.
53. (Amended) A method of decreasing or inhibiting one or more symptoms of the common cold in a subject comprising administering to a subject having a common cold an amount of a humanized antibody of claim ~~21~~ 22 effective to decrease or inhibit one or more symptoms of the common cold in the subject.

54. (Previously Presented) The method of claim 53, wherein the humanized antibody is administered locally.
55. (Amended) The method of claim 53, wherein the humanized antibody is administered via inhalation or ~~intranasally~~ intranassally.
56. (Previously Presented) The method of claim 53, wherein the subject has or is at risk of having asthma.
57. (Previously Presented) The method of claim 53, wherein the subject is a newborn or between the ages of 1 to 5, 5 to 10 or 10 to 18.

Please add the following new claims:

58. (New) The humanized antibody of claim 4, wherein said substitution is in a complementarity determining region.
59. (New) The humanized antibody of claim 4, wherein said substitution is in a framework region.
60. (New) The humanized antibody of claim 4, wherein said substitution comprises 5-10 amino acids.
61. (New) The humanized antibody of claim 4, wherein said substitution comprises 3-5 amino acids.
62. (New) The humanized antibody of claim 4, wherein said substitution comprises 1-3 amino acids.
63. (New) The humanized antibody of claim 4, wherein the antibody binds ICAM-1 with increased affinity relative to humanized antibody having the complementarity regions of mouse monoclonal antibody denoted as 1A6.
64. (New) The humanized antibody of claim 4, wherein the antibody has an ICAM-1 binding affinity 4-fold greater than humanized antibody having the complementarity regions of mouse monoclonal antibody denoted as 1A6.
65. (New) The humanized antibody of claim 4, wherein the antibody has an ICAM-1 binding affinity 5-fold greater than humanized antibody having the complementarity regions of mouse monoclonal antibody denoted as 1A6.

66. (New) The humanized antibody of claim 4, wherein the antibody has an ICAM-1 binding affinity 5 to 8-fold greater than humanized antibody having the complementarity regions of mouse monoclonal antibody denoted as 1A6.
67. (New) The humanized antibody of claim 4, wherein the antibody has an ICAM-1 binding affinity 5 to 10-fold greater than humanized antibody having the complementarity regions of mouse monoclonal antibody denoted as 1A6.
68. (New) The humanized antibody of claim 4, wherein the antibody has an ICAM-1 binding affinity 8 to 15-fold greater than humanized antibody having the complementarity regions of mouse monoclonal antibody denoted as 1A6.
69. (New) The humanized antibody of claim 4, wherein the antibody has an ICAM-1 binding affinity 10 to 20-fold greater than humanized antibody having the complementarity regions of mouse monoclonal antibody denoted as 1A6.
70. (New) The humanized antibody of claim 4, wherein the antibody has an ICAM-1 binding affinity 20 to 40-fold greater than humanized antibody having the complementarity regions of mouse monoclonal antibody denoted as 1A6.
71. (New) The humanized antibody of claim 4, wherein the antibody has an ICAM-1 binding affinity 50 to 100-fold greater than humanized antibody having the complementarity regions of mouse monoclonal antibody denoted as 1A6.
72. (New) The humanized antibody of claim 4, wherein the antibody has an ICAM-1 binding affinity 100-fold or greater than humanized antibody having the complementarity regions of mouse monoclonal antibody denoted as 1A6.
73. (New) The humanized antibody of claim 4, wherein the antibody binds ICAM-1 with an affinity at least equivalent to mouse monoclonal antibody denoted as 1A6.
74. (New) The humanized antibody of claim 4, wherein the antibody binds ICAM-1 with increased affinity relative to mouse monoclonal antibody denoted as 1A6.
75. (New) The humanized antibody of claim 4, wherein the antibody has an ICAM-1 binding affinity 4-fold greater than mouse monoclonal antibody denoted as 1A6.
76. (New) The humanized antibody of claim 4, wherein the antibody has an ICAM-1 binding affinity 5-fold greater than mouse monoclonal antibody denoted as 1A6.
77. (New) The humanized antibody of claim 4, wherein the antibody has an ICAM-1 binding affinity 5 to 8-fold greater than mouse monoclonal antibody denoted as 1A6.

78. (New) The humanized antibody of claim 4, wherein the antibody has an ICAM-1 binding affinity 5 to 10-fold greater than mouse monoclonal antibody denoted as 1A6.
79. (New) The humanized antibody of claim 4, wherein the antibody has an ICAM-1 binding affinity 8 to 15-fold greater than mouse monoclonal antibody denoted as 1A6.
80. (New) The humanized antibody of claim 4, wherein the antibody has an ICAM-1 binding affinity 10 to 20-fold greater than mouse monoclonal antibody denoted as 1A6.
81. (New) The humanized antibody of claim 4, wherein the antibody has an ICAM-1 binding affinity 20 to 40-fold greater than mouse monoclonal antibody denoted as 1A6.
82. (New) The humanized antibody of claim 4, wherein the antibody has an ICAM-1 binding affinity 50 to 100-fold greater than mouse monoclonal antibody denoted as 1A6.
83. (New) The humanized antibody of claim 4, wherein the antibody has an ICAM-1 binding affinity 100-fold or greater than mouse monoclonal antibody denoted as 1A6.